Evidence map›Paper›PMID 16084395›Full record

ReviewProtein expression and purification2005

SUMO fusion technology for difficult-to-express proteins.

Tauseef R Butt, Suzanne C Edavettal, John P Hall, Michael R Mattern

Abstract readReview
In one paragraph

Review in Protein expression and purification, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed.

  1. Facile, high-throughput protein purification enabled by high-efficiency protease elution.Protein science : a publication of the Protein Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A Simple Method to Produce Recombinant Mammalian Serum Albumins inInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tauseef R ButtLifeSensors, Inc., 271 Great Valley Parkway, Malvern, PA 19355, USA. butt@lifesensors.com
Suzanne C Edavettal
John P Hall
Michael R Mattern

Funding

Multivalent Antigen Expression and Vaccine for MalariaR43AI051752 · NIAID · LIFESENSORS, INC. · PI BUTT, TAUSEEF R. · 2002 to 2003
$637k
A Fusion System to Prolong Plasma Half-Life of ProteinsR43AI058584 · NIAID · LIFESENSORS, INC. · PI BUTT, TAUSEEF R. · 2004 to 2005
$623k
SUMO Fusions to Enhance Protein Expression &SecretionR43GM068404 · NIGMS · LIFESENSORS, INC. · PI BUTT, TAUSEEF R. · 2003 to 2004
$369k
Secretion of Ubiquitin-fusion ProteinsR43HL069744 · NHLBI · LIFESENSORS, INC. · PI BUTT, TAUSEEF R. · 2001 to 2002
$327k
SUMO Fusion For Genome Wide Protein AnalysisR43GM067271 · NIGMS · LIFESENSORS, INC. · PI BUTT, TAUSEEF R. · 2003 to 2003
$225k
NHLBI NIH HHS R43 HL 69744NIAID NIH HHS 1R43-AI058584-01A1NIAID NIH HHS R43 AI058584NIAID NIH HHS R43 AI 51752NIGMS NIH HHS R43 GM 067271NIGMS NIH HHS R43 GM067271NIGMS NIH HHS R43 GM 068404NIGMS NIH HHS R43 GM068404
6 · The paper itself

Abstract

The demands of structural and functional genomics for large quantities of soluble, properly folded proteins in heterologous hosts have been aided by advancements in the field of protein production and purification. Escherichia coli, the preferred host for recombinant protein expression, presents many challenges which must be surmounted in order to over-express heterologous proteins. These challenges include the proteolytic degradation of target proteins, protein misfolding, poor solubility, and the necessity for good purification methodologies. Gene fusion technologies have been able to improve heterologous expression by overcoming many of these challenges. The ability of gene fusions to improve expression, solubility, purification, and decrease proteolytic degradation will be discussed in this review. The main disadvantage, cleaving the protein fusion, will also be addressed. Focus will be given to the newly described SUMO fusion system and the improvements that this technology has advanced over traditional gene fusion systems.

Indexed as

Escherichia coliGene ExpressionGene FusionProtein FoldingRecombinant Fusion ProteinsSmall Ubiquitin-Related Modifier ProteinsRecombinant Fusion ProteinsSmall Ubiquitin-Related Modifier Proteins

Identifiers

PMID16084395
PMCPMC7129290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.